Regarding DM, a joint statement from Italian societies of Endocrinology and of Diabetes previously reported that an improvement of glycaemic profile is expected for all compounds except for pasireotide [52]; a recent phase IV study showed the important role of incretin-based antidiabetic drugs in this latter setting [53]. The gene discussed is GCG; the disease is diabetes mellitus.